Ductal Carcinoma in Situ (DCIS) is a condition where the cells lining the milk ducts (the channels in the breast that carry milk to the nipple) are cancerous, but stay contained within the ducts without growing through into the surrounding breast tissue. DCIS may affect just one area of the breast, but can be more widespread and affect different areas at the same time. Sometimes DCIS may be described as pre-cancerous, pre-invasive, non-invasive, or intraductal cancer.
The addition of the monoclonal antibody therapy Trastuzumab to radiotherapy did not reach the protocol objective of a 36% reduction in the ipsilateral breast tumor recurrence rate for women with HER2-positive ductal carcinoma in situ (DCIS) on the NRG Oncology clinical trial NSABP B-43.
A high-resolution, three-dimensional imaging technique, when combined with quantitative measurement of tissue elasticity, could accurately detect cancer within the resected margins of surgical specimens taken from patients undergoing breast-conserving surgery.
Ductal carcinoma in-situ (DCIS) accounts for one-fifth of breast cancer cases in the United States, according to the American Cancer Society.
New research at Case Western Reserve University could help better determine which patients diagnosed with the pre-malignant breast cancer commonly as stage 0 are likely to progress to invasive breast cancer and therefore might benefit from additional therapy over and above surgery alone.
Older women with a very early, non-invasive breast cancer known as ductal carcinoma in situ (DCIS) gain no long-term benefit from undergoing a sentinel lymph node biopsy to see if the cancer has spread, new research by the Yale School of Public Health has found.
Six factors were associated with invasive recurrence of breast cancer after a diagnosis of ductal carcinoma in situ (DCIS), according to data from a meta-analysis.
A subset of patients with low-risk breast cancer is highly unlikely to see cancer return following breast conservation surgery but can lower that risk even further with radiation therapy, finds a new long-term clinical trial report.
A research team, led by investigators from Georgetown Lombardi Comprehensive Cancer Center, details how a natural and dramatic process -- changes in mammary glands to accommodate breastfeeding -- uses a molecular process believed to contribute to survival of pre-malignant breast cells.
Lumpectomy plus radiation was associated with a small clinical benefit in reduced risk of breast cancer death compared with lumpectomy or mastectomy alone in women with ductal carcinoma in situ, a noninvasive early form of breast cancer.
Australian researchers have asked for changes in the way doctors tend to label low risk cancerous conditions as “cancer” leading to over treatment. Certain diagnoses such as localised prostate cancer or “stage 0” breast cancers need to be looked at say the researchers at the University of Sydney and Bond University to prevent aggressive treatment where it is not needed.
A new genetic-based model may explain how a common form of early-stage breast cancer known as ductal carcinoma in situ progresses to a more invasive form of cancer say researchers at The University of Texas MD Anderson Cancer Center.
The detection of certain non-cancerous "high risk" breast lesions can lead to surgical treatment in women, but one of the largest studies of a specific type of high-risk lesion, flat epithelial atypia (FEA), calls for close observation, rather than surgical removal of these lesions in most cases, according to study results published on the web site of the Journal of the American College of Surgeons in advance of print.
Cleveland Clinic researcher Chirag Shah, M.D., led the development of updated guidelines for the appropriate and safe utilization of accelerated partial-breast irradiation. The guidelines are published online in the journal, Brachytherapy.
Three major national databases include varying estimates of racial gaps in the use of immediate breast reconstruction (IBR) after mastectomy for breast cancer, reports a study in the March issue of Plastic and Reconstructive Surgery, the official medical journal of the American Society of Plastic Surgeons.
Women over 50 who have been treated for ductal carcinoma in situ (DCIS) are more likely to be alive ten years later than women in the general population, according to new research presented at the European Cancer Congress 2017.
Deregulation and inhibition of the immune system contributes to cancer development. Many therapeutic strategies aim to restimulate the immune system to recognize cancer cells and target them for destruction.
A supplemental "boost" of radiation improves local control and provides an incremental benefit in decreasing breast cancer recurrence for patients with Ductal Carcinoma In Situ (DCIS) who receive whole breast radiation therapy radiation (WBRT) following lumpectomy, according to research presented today at the 58th Annual Meeting of the American Society for Radiation Oncology.
The American Society for Radiation Oncology has chosen Theresa A. Keresztes, a resident of Wellesley, Massachusetts, to receive the 2016 Survivor Circle Award.
Delaying radiation therapy too long after surgery significantly increases the risk of recurrent tumors in women treated for very early, or what is referred to as "stage 0," breast cancer, according to new research at Washington University School of Medicine in St. Louis.
If followed, new U.S. Preventive Services Task Force breast cancer screening recommendations will result in thousands of unnecessary deaths each year and thousands more women enduring extensive and expensive treatment than if their cancer had been found early by an annual mammogram.